<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231217</url>
  </required_header>
  <id_info>
    <org_study_id>GTCD-01</org_study_id>
    <nct_id>NCT01231217</nct_id>
  </id_info>
  <brief_title>Green Tea in Crohn's Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Heidelberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether green tea or coffee influence the course and
      life quality of patients with mild to moderately active Crohn's disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Crohn's Disease Activity Index</measure>
    <time_frame>week 16</time_frame>
    <description>Assessment of clinical activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Harvey-Bradshaw-Index</measure>
    <time_frame>week 16</time_frame>
    <description>Assessment of clinical activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Bowel Disease Questionnaire</measure>
    <time_frame>week 16</time_frame>
    <description>Assessment of Life Quality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>green (or white) tea</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are recommended to drink green (or white) tea but are not allowed to consume any coffee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>coffee</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients are recommended to drink coffee but are not allowed to consume any tea</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Green tea (Camellia sinensis)</intervention_name>
    <description>Patients are recommended to drink at least 5 cups of green tea per day</description>
    <arm_group_label>green (or white) tea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Coffee</intervention_name>
    <description>Patients are recommended to drink as much coffee as they tolerate.</description>
    <arm_group_label>coffee</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women and men ≥ 18 years with signed informed consent,

          -  Patients with proven Crohn's disease,

          -  Chronic-active course ≥ 3 months,

          -  Current CDAI ≥ 150 and ≤ 350,

          -  All medications for Crohn's disease have to be on a constant dosage for at least 4
             weeks prior to study entry (i.e. 5-ASA, steroids),

          -  Ability of the participant to understand character and individual consequences of the
             study.

        Exclusion Criteria:

          -  Pregnancy or the wish to become pregnant, breastfeeding,

          -  Concomitant treatment with methotrexate, azathioprine or 6-mercaptopurine for &lt; 3
             months,

          -  Treatment with TNF-alpha-antagonists, cyclosporine or tacrolimus &lt; 4 weeks prior to
             study entry,

          -  Participation in another study within the last 4 weeks,

          -  Ulcerative colitis or indeterminate colitis,

          -  Infectious colitis, including cytomegalovirus or Clostridium difficile induced
             colitis,

          -  Colitis for other reasons like known diverticulitis, radiation colitis, ischemic
             colitis or microscopic colitis,

          -  Malabsorption syndromes, lactose intolerance, celiac disease, exocrine pancreas
             insufficiency,

          -  Bleeding hemorrhoids,

          -  Other inflammatory or bleeding disorders of the colon and intestine, or diseases that
             may cause diarrhea or gastrointestinal bleeding,

          -  Intolerance / aversion to tea and/or coffee,

          -  Current treatment with antibiotics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Max Karner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anja Hanemann, MS</last_name>
    <phone>00496221568701</phone>
    <email>anja.hanemann@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Max Karner, MD</last_name>
    <email>max.karner@email.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Hanemann, MS</last_name>
      <phone>00496221568701</phone>
      <email>anja.hanemann@med.uni-heidelberg.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2010</study_first_submitted>
  <study_first_submitted_qc>October 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2010</study_first_posted>
  <last_update_submitted>October 29, 2010</last_update_submitted>
  <last_update_submitted_qc>October 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2010</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

